Latest News - AbbVie
Top Corporates Hub
AbbVie
AbbVie, Alloy Therapeutics Ink Deal to Develop Next-Gen Antibody Platform
20.03.2026 04:29
AbbVie Inc. (NYSE:ABBV) is included among the 15 Dividend Stocks to Buy for Steady Income. On March 17, Alloy Therapeutics announced an agreement with AbbVie Inc. (NYSE:ABBV) to develop a new antibody platform. The goal is to discover potent and specific antibodies for targets that current technologies struggle to address. Under the multi-year deal, Alloy […]
Breckenridge announces launch of Milnacipran HCl Tablets, generic equivalent of Savella®
19.03.2026 15:35
Breckenridge Pharmaceutical, Inc., the U.S. subsidiary of Towa International that markets, distributes, and sells generic medicines in the United States, today announced the launch of Milnacipran HCl Tablets, the generic equivalent of Savella® by AbbVie, in the pain management category.
Switzerland risks the ire of the White House as it flags potential currency intervention
19.03.2026 11:08
The Swiss National Bank said Thursday that it is growing increasingly willing to intervene in foreign exchange markets.
Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions
19.03.2026 07:00
Allergan Aesthetics, an AbbVie company (NYSE: ABBV) and global leader in medical aesthetics, today announced new global consumer research highlighting how patient expectations in medical aesthetics are evolving, and will present the next evolution of its AA Signature™ framework, to address this changing treatment need, at the AMWC 2026 in Monaco.
Assessing AbbVie (ABBV) Valuation After The Recent Share Price Pullback
19.03.2026 04:30
Recent performance snapshot for AbbVie (ABBV) AbbVie (ABBV) has been under pressure recently, with the share price showing a 5.2% decline over the past day and an 8.5% drop over the past week, closing at US$208.34. Short term weakness has also extended into the past month and past 3 months. The stock is down 10.0% and 6.5% respectively, while the 1 year total return remains positive at 1.5%. See our latest analysis for AbbVie. Recent selling has pulled AbbVie’s share price down in the short...
Wednesday's session: gap up and gap down stock in the S&P500 index
18.03.2026 15:35
Wednesday's session is showcasing interesting market movements in the S&P500 index, with notable gap up and gap down stocks. Stay updated with the gapping S&P500 stocks in today's session.
Allergan Aesthetics Redefines Skin Quality Communication with Launch of Skin Quality Index
16.03.2026 12:00
Allergan Aesthetics, an AbbVie company, today announced the launch of the Skin Quality Index (SQI), a unified vocabulary developed to standardize how patients and health care providers discuss skin quality. The framework is supported by the most comprehensive global research to date published in Dermatologic Surgery, which identified inconsistencies in terminology used by patients and providers, and highlighted the need for clearer, more consistent language during aesthetic consultations.
If You Have $500,000 Saved at 60, Here’s The Sort of Monthly Income You Can Count On
13.03.2026 13:12
At 60 with $500,000 saved, you are closer to a workable retirement income than most people realize. The math is concrete, the variables are manageable, and the biggest decision you will make has nothing to do with which stocks to pick. Key Fact Detail Age 60 years old Savings $500,000 Core issue How much monthly ... If You Have $500,000 Saved at 60, Here’s The Sort of Monthly Income You Can Count On
RBC Capital Says AbbVie Inc. (ABBV) Growth Story Is Still in Early Stages
12.03.2026 06:26
AbbVie Inc. (NYSE:ABBV) ranks among the 14 safe stocks to buy now for a starter stock portfolio. On February 24, RBC Capital began coverage of AbbVie Inc. (NYSE:ABBV) with an Outperform rating and a price target of $260. While mainstream opinion appears to be catching up on the company’s Skyrizi and Rinvoq sales, the firm […]
AbbVie Reports Promising Results from Phase 1 Study of ABBV-295
12.03.2026 05:21
AbbVie Inc. (NYSE:ABBV) is included among the 13 Undervalued Dividend Aristocrats to Buy Now. AbbVie Inc. (NYSE:ABBV) is a research-based biopharmaceutical company that engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. On March 9, AbbVie Inc. (NYSE:ABBV) reported encouraging results from a phase 1 study of its ABBV-295 […]
How The Narrative For AbbVie (ABBV) Is Shifting On Immunology Growth And Competition Risks
12.03.2026 01:12
AbbVie’s model based fair value has been adjusted only slightly, moving from US$248.29 to US$248.86, which keeps the overall price target essentially stable in dollar terms. That small change sits alongside a split analyst view, where some see room for upside tied to immunology growth and pipeline progress, while others focus on competition risk and a more balanced risk and reward trade off at current levels. As you read on, you will see how these competing views shape the evolving AbbVie...
Market Downturn: 2 Stocks to Buy and Hold Through Any Storm
11.03.2026 14:05
These companies are highly unlikely to go under, no matter what happens.
Powering AI: Europe switches on its first microgrid-connected data center
11.03.2026 02:00
AVK and Pure Data Centers’ microgrid facility in Ireland could mark the region’s first step toward a privately powered ecosystem.
Elahere (AbbVie: mirvetuximab soravtansine-gynx) Market Research Report 2026: Epidemiology, Competitive Landscape, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F
10.03.2026 09:14
Opportunities in the Elahere market include the rising incidence of ovarian cancer, increased precision oncology adoption, FR alpha-targeted treatments, and regulatory approvals expansion. Strategic acquisitions enhance ADC capabilities, while localized manufacturing addresses tariff impacts to bolster market presence.Dublin, March 10, 2026 (GLOBE NEWSWIRE) -- The "Elahere Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's
AbbVie Trial Updates Add Context To Valuation And Growth Outlook
09.03.2026 13:10
AbbVie (NYSE:ABBV) reported positive Phase 3 results for risankizumab in Crohn's disease, supporting a potential expansion of its use in this condition. The company also released encouraging early-stage data for ABBV-295, a non-incretin-based candidate being studied for chronic weight management. AbbVie is drawing fresh attention with these pipeline updates at a time when its shares trade around $230.11 and have returned 9.8% over the past year and 152.7% over the past 5 years. For...
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
09.03.2026 13:00
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults
09.03.2026 12:00
AbbVie (NYSE: ABBV) today announced positive topline results1 from the multiple ascending dose (MAD) part of its Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneous ABBV-295, in adults with a mean body mass index (BMI) of less than 30 kg/m2. ABBV-295 is a long-acting amylin analog that represents a mechanistically distinct class from incretin-based therapies such as GLP-1 and GIP receptor agonists.
AbbVie Inc. (ABBV) Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI Subcutaneous Induction in Patients with Crohn’s Disease
09.03.2026 08:46
AbbVie Inc. (NYSE:ABBV) is one of the best undervalued stocks to invest in right now. AbbVie Inc. (NYSE:ABBV) announced on March 2 positive topline results from the Phase 3, randomized, placebo-controlled, double-blind AFFIRM study evaluating the efficacy and safety of risankizumab subcutaneous induction treatment versus placebo in adult patients with moderately to severely active Crohn’s disease. […]
AbbVie Shares Topline Data From Multiple Ascending Dose Part Of Phase 1 Study Of Subcutaneous ABBV-295 In Obese Patients
09.03.2026 08:13
ABBV-295 treatment showed clinically meaningful body weight reduction from -7.75% to -9.79% (least-squares mean) at week 12 (weekly dosing), to -7.86% to -9.73% at week 13 (every other week and monthly dosing after week
Is AbbVie (ABBV) Still Priced Attractively After Its Strong Multi Year Share Price Run
07.03.2026 02:10
If you are wondering whether AbbVie is still reasonably priced after a strong multi year run, the key issue is how its current share price compares with different measures of value. AbbVie recently closed at US$230.11, with returns of 0.3% year to date, 11.0% over 1 year and 157.5% over 5 years. Over the last 7 days the share price declined 0.8%, while it gained 6.0% over the past month. This mix of shorter and longer term performance can leave investors unsure whether the stock now reflects...